pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$SNYSanofi

$SNY46.52+1.00%
Paris, FRupdated 2h ago

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in the Forbes Global 2000 was 89.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval433 co-mentions · 217 sources
  • company$SNYNFSanofi234 co-mentions · 225 sources
  • drugRIFADIN233 co-mentions · 117 sources
  • tagSmall Molecule168 co-mentions · 168 sources
  • drugrifampin117 co-mentions · 117 sources
  • drugRIFATER50 co-mentions · 25 sources
  • drugPRIMAQUINE36 co-mentions · 18 sources
  • drugrifapentine34 co-mentions · 17 sources
pipeline
27
marketed
1
phase 3
9
catalysts ytd
7
approvals ytd
1
recalls ytd
0

Pipeline(27)

view full pipeline →
pipeline depth27 products
Preclinical: 1Phase 1: 2Phase 2: 12Phase 3: 9Marketed: 1pre_registration: 2
1Preclinical2Phase 112Phase 29Phase 31Marketed2pre_registration
Marketed
rilzabrutinib
Acquired (Autoimmune) Hemolytic Anemia
Tyrosine-protein kinase BTK
Phase 3
Coronavirus Disease 2019 (COVID-19) vaccine
Coronavirus Disease 2019 (COVID-19)
Spike glycoprotein
Phase 3
Fluzone QIV HD
Unspecified Influenza Virus Infections
Phase 3
SP-0218
Yellow Fever
Phase 3
VerorabVax
Rabies
Phase 3
avalglucosidase alfa
Pompe Disease
Phase 3
frexalimab
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3
gusacitinib hydrochloride
Hand Dermatitis
Phase 3
riliprubart
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3
venglustat malate
Fabry Disease
Phase 2
IIV-HD + rC19
Coronavirus Disease 2019 (COVID-19)
Phase 2
RIV3 + rC19
Coronavirus Disease 2019 (COVID-19)

📅 Upcoming

Jan 28, 2027
earnings
$SNY46.52+1.00%
in 2mo
Sanofi earnings
Sanofi
→

🕒 Recent(90d)

earnings (1)
Oct 30, 2026
earnings
$SNY46.52+1.00%
22d ago
Sanofi earnings
Sanofi
→
view all catalysts →

Active trials

  • phase2A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)terminatedn=7
  • phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Diseaserecruitingn=751
  • —A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumabactive not recruitingn=303
  • phase2A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Diseaserecruitingn=99
  • phase3A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemiarecruitingn=90
  • —A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)completedn=9
  • —A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korearecruitingn=3,000
  • phase4Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophyrecruitingn=35
🐶 Hiring Signal
next earnings Jan 28, 2027
778 open roles at Sanofi →

Where Sanofi is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaInfectious Disease & Vaccines 36Hematology 28Immunology & Inflammation 23Oncology 22Respiratory 18CNS / Neuroscience 11
departmentIT & Engineering 44Commercial 43Medical Affairs 37Business Development & Sales 33Manufacturing / CMC 32Quality 28

News

  • ICE detention of Princeton scientist rattles academia
    A graduate student who is a scientific researcher at Princeton was detained by ICE while traveling home after presenting at a neuroscience conference.
    stat · 2h ago
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 8h ago
  • An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
    If it came to fruition, the rumored deal between Sanofi and Insmed would likely be the year’s largest, with one analyst putting a potential value for the biotech as high as $40 billion.
    biospace · 9h ago
  • STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
    Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
    stat · 10h ago
  • STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
    Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
    stat · 10h ago
  • Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
    Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
    biopharma_dive · 11h ago
  • Sanofi's Infilbray wins first approval for neurological symptoms of Gaucher
    Sanofi won FDA approval Wednesday for Infilbray, the first drug in the US to treat the neurological symptoms of a rare genetic disorder called Gaucher disease. Infilbray, also known as venglustat,…
    endpoints · 1d ago
  • Sanofi gains FDA clearance for Gaucher disease pill
    The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
    biopharma_dive · 1d ago
  • Sanofi considering a deal to acquire Insmed, according to report
    Sanofi is looking at a deal to buy the US drugmaker Insmed, Bloomberg News reported Thursday, in what would be one of the biggest biopharma takeovers of the last several years. The Bloomberg report…
    endpoints · 1d ago
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    biospace · 1d ago
view all news mentions →
identifiers
ticker
$SNY
SEC CIK
0001121404
country
FR
source
sec_tickers
top tags
Infectious Disease9Immunology2Oncology2Ophthalmology2AMD1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?